Is breast cancer a potential side effect of GH treatment?

Photothermal therapy, assisted by local heat generation using photothermal nanoparticles (NPs), is an emerging strategy to treat tumors noninvasively. To improve treatment outcome and to alleviate potential side effect on...

Download Full-text

Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis

Case Reports in Gastroenterology ◽

10.1159/000514952 ◽

2021 ◽

pp. 662-666

Author(s):

Mitra Barahimi ◽

Scott Lee ◽

Kindra Clark-Snustad

Keyword(s):

Side Effect ◽

De Novo ◽

Pustular Psoriasis ◽

Initial Weight ◽

Drug Induced ◽

Clinical Recurrence ◽

Potential Side Effect ◽

First Case ◽

Tnf Antagonist ◽

Subcorneal Pustular Dermatosis

We report the case of a 51-year-old male with Crohn’s disease (CD) who developed a reproducible pustular rash after ustekinumab (UST) administration. The patient first presented with a pustular rash on his hands, body, extremities, and scalp starting 5 weeks after his initial weight-based UST induction. The rash resolved spontaneously, then recurred 4 weeks after his first subcutaneous maintenance dose of UST 90 mg. Biopsy of the affected area demonstrated subcorneal pustular dermatosis (SPD). UST was discontinued and the rash resolved. Unfortunately, the patient experienced clinical recurrence of CD, and given prior failure of multiple CD medications, UST was restarted with premedication. Two weeks after UST re-induction, the rash recurred, though less severe. Given improvement in CD symptoms, UST was continued and the rash managed with topical corticosteroids. This is the first case of drug-induced SPD associated with UST. One case report has previously described de novo pustular psoriasis associated with UST in a patient with CD and enteropathic arthritis. Notably, SPD and pustular psoriasis can be histologically indistinguishable. The development of a paradoxical psoriasiform rash is thought to be one of the few dose and duration dependent side effects of TNF-antagonist therapy but has not previously been established as a side effect of UST. This case demonstrates a new potential side effect of UST.

Download Full-text

Is Fatigue a Long-term Side Effect of Breast Cancer Treatment?

Cancer Control ◽

10.1177/107327489900600304 ◽

1999 ◽

Vol 6 (3) ◽

pp. 256-263 ◽

Cited By ~ 55

Author(s):

Paul B. Jacobsen ◽

Kevin Stein

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Side Effect ◽

Breast Cancer Treatment

Download Full-text

Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2000.18.20.3487 ◽

2000 ◽

Vol 18 (20) ◽

pp. 3487-3494 ◽

Cited By ~ 85

Author(s):

Kaija Holli ◽

Ritva Valavaara ◽

Guillermo Blanco ◽

Vesa Kataja ◽

Päivi Hietanen ◽

...

Keyword(s):

Breast Cancer ◽

Side Effect ◽

Cancer Recurrence ◽

Breast Cancer Recurrence ◽

Side Effect Profile ◽

Treatment Groups ◽

Node Positive ◽

Er Positive ◽

The Mean

PURPOSE: In this multicenter trial, toremifene 40 mg/d was compared with tamoxifen 20 mg/d, both given orally for 3 years to postmenopausal, axillary node–positive women after breast surgery. PATIENTS AND METHODS: The first 899 patients (toremifene, n = 459; tamoxifen, n = 440) of the total of 1,480 patients accrued to the trial were included in this scheduled safety analysis. The mean follow-up time was 3.4 years. RESULTS: The two treatment groups were well balanced with respect to patient and disease characteristics. The subjective side-effect profile was similar in both treatment groups. Slightly more vascular complications (deep vein thromboses, cerebrovascular events, and pulmonary embolisms) were seen among tamoxifen-treated patients (5.9%) as compared with toremifene-treated patients (3.5%) (P = .11), whereas bone fractures (P = .09) and vaginal leukorrhea (P = .05) were more common in the toremifene group. The number of subsequent second cancers was similar. The breast cancer recurrence rate was 23.1% (n = 106) in the toremifene group and 26.1% (n = 115) in the tamoxifen group (P = .31). When only patients with estrogen receptor (ER)–positive cancer were considered (n = 556), the risk for breast cancer recurrence was nonsignificantly lower among the toremifene-treated women, with a hazards ratio of 0.74 (90% confidence interval, 0.52 to 1.04; P = .14). The mean time to breast cancer recurrence and overall survival were similar in both groups. CONCLUSION: The side-effect profile of toremifene resembles that of tamoxifen. The efficacy of toremifene seems to be no less than that of tamoxifen. The trend for fewer breast cancer recurrences in the ER-positive subgroup is encouraging, but a longer follow-up is needed to confirm this.

Download Full-text

HUBUNGAN ANTARA NAFSU MAKAN DENGAN ASUPAN ENERGI DAN PROTEIN PADA PASIEN KANKER PAYUDARA POST KEMOTERAPI[Correlation between Appetite with Energy and Protein Intake of Post Chemotherapy Breast Cancer Patients]

Media Gizi Indonesia ◽

10.20473/mgi.v14i2.170-176 ◽

2019 ◽

Vol 14 (2) ◽

pp. 170

Author(s):

Silviana Putri ◽

Merryana Adriani ◽

Yayuk Estuningsih

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Side Effect ◽

Protein Intake ◽

Pearson Correlation ◽

Observational Research ◽

Breast Cancer Patients ◽

Cross Sectional ◽

Chemotherapy Drugs ◽

Pearson Correlation Test

Chemotherapy drugs used to kill or inhibit proliferation of cancer cell that are cytotoxic and causing side effect for breast cancer patients. The side effect of chemotherapy drugs is decreasing the appetite which causing decrease in energy and protein intake, and could affect nutritional status. This study aim to determine the relationship between appetite with energy and protein intake of post chemotherapy breast cancer patients. This research was an analytic observational research using cross sectional design and purposive sampling conducted at Dr. Ramelan Navy Hospital Surabaya with a sample size of 50 patients. Correlation between appetite with energy and protein intake were analyzed using Pearson correlation. The average of energy and protein intake were 976.3±304.2 kcal and 29.4±12.9 g. Pearson correlation test showed signifi cant correlation between appetite as chemoteraphy side effect with energy intake (p=0.000; r=-0.558) and protein intake (p=0.000; r=-0.504). Decreasing of appetite due to chemoterapy reduce the energy and protein intake of breast cancer patient. Patient are suggest to consume foods in small portion but often to maintain adequate energy and protein intake.

Download Full-text

Propagation of Economic Inequality Through Reciprocity and Reputation

Psychological Science ◽

10.1177/0956797617741720 ◽

2018 ◽

Vol 29 (4) ◽

pp. 604-613 ◽

Cited By ~ 9

Author(s):

Leor M. Hackel ◽

Jamil Zaki

Keyword(s):

Reinforcement Learning ◽

Side Effect ◽

Formal Model ◽

Economic Inequality ◽

Social Processes ◽

Social Phenomena ◽

Potential Side Effect ◽

Economic Games ◽

Broad Scale

Reciprocity and reputation are powerful tools for encouraging cooperation on a broad scale. Here, we highlight a potential side effect of these social phenomena: exacerbating economic inequality. In two novel economic games, we manipulated the amount of money with which participants were endowed and then gave them the opportunity to share resources with others. We found that people reciprocated more toward higher-wealth givers, compared with lower-wealth givers, even when those givers were equally generous. Wealthier givers also achieved better reputations than less wealthy ones and therefore received more investments in a social marketplace. These discrepancies were well described by a formal model of reinforcement learning: Individuals who weighted monetary outcomes, rather than generosity, when learning about interlocutors also most strongly helped wealthier individuals. This work demonstrates that reciprocity and reputation—although globally increasing prosociality—can widen wealth gaps and provides a precise account of how inequality grows through social processes.

Download Full-text